Support provided by an independent educational grant from Allergan, Astellas and Medtronic

CME Available: https://auau.auanet.org/node/24581

Instructional Course Director(s)

Kathleen Kobashi, MD, FACS, FPMRS

Virginia Mason Medical Center

Instructional Course Faculty(s)

Sandip Vasavada, MD

Professor of Surgery/Urology

Cleveland Clinic Glickman Urological Institute and Lerner College of Medicine

David Ginsberg, MD

USC Institute of Urology

This course would aim to discuss all guidelines-approved 3rd line therapies for the treatment of overactive bladder (OAB). Case–based discussion will be used adjunctively to illustrate how best to select patients in varying clinical scenarios and how to optimally counsel a patient on each of the available modalities, including onabotulinumtoxinA injection of the bladder, tibial nerve stimulation, and sacral nerve stimulation (SNS). Emerging therapies in neuromodulation will also be introduced.

Optimal patient selection and integration of these therapies into the urology practice will be discussed in detail. Importantly, the technique of onabotulinumtoxinA injection, ideal tibial nerve stimulation, optimal SNS lead placement, and troubleshooting of the failed implant will be highlighted.

Learning Objectives:

Name the available 3rd line therapies for treatment of refractory OAB

Practice the the injection technique for onabotulinumtoxinA for OAB

Employ the technique of tibial nerve stimulation for OAB

Indicate the optimal lead placement for sacroneuromodulation and troubleshooting the failed implant

Identify the upcoming 3rd line therapies for OAB